[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592585":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":51,"collaborators":54,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":25,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":25,"overallStatus":33,"whyStopped":25,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","ACTIVE_COMPARATOR","patients will receive febuxostat 80 mg daily for 6 months.",[13],"Drug: Febuxostat Tablets",{"label":15,"type":10,"description":16,"interventionNames":17},"Metformin group","patients will receive metformin 1000 mg daily for 6 months",[13,18],"Drug: Metformin",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Febuxostat Tablets","Febuxostat is a selective xanthine oxidase inhibitor (XOI) that targets uric acid generation. It has been used as a SUA lowering agent in patients not responding to allopurinol",[9,15],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Metformin","Metformin is an oral antihyperglycemic drug widely used in type 2 diabetes (T2DM) treatment. Most of its effects are exerted via an indirect induction of the phosphorylated activation of AMP-activated protein kinase (AMPK)",[15],[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Mostafa Bahaa","RECRUITING","Damietta","New Damietta","34518","Egypt","EG",{"type":40,"coordinates":41},"Point",[42,43],31.81332,31.41648,{"lat":43,"lon":42},[46],{"name":47,"role":48,"phone":49,"phoneExt":25,"email":50},"Mostafa Bahaa, PhD","CONTACT","0201025538337","mbahaa@horus.edu.eg",{"type":52,"investigatorFullName":32,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Lecturer",[55,58,60],{"name":56,"class":57},"Dalia Naser Abdel-Sadek Safa , Faculty of Pharmacy, Tanta University","UNKNOWN",{"name":59,"class":57},"Sahar Mohamed Elhaggar, Faculty of Pharmacy, Tanta University",{"name":61,"class":57},"Tarek Mohamed Abd-Elazez Nasr-Allah, Faculty of Medicine - Al-Azhar University","100592585","phase-2-comparative-clinical-and-biochemical-study-evaluating-the-effectiveness-of-metformin-versus-febuxostat-on-gouty-obese-non-diabetic-patients-100592585",false,"NCT06995339","Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients","Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostate on Gouty Obese Non-Diabetic Patients","Inclusion Criteria:\n\n* Males or females aged \\\u003C 18 years.\n* All patients are diagnosed to have gout with serum uric acid \\\u003C 7 mg\u002Fdl.\n* All patients are diagnosed to have obesity with body mass index (BMI) ≥ 30 kg\u002Fm2.\n\nExclusion Criteria:\n\n* The presence of any type of diabetes mellitus.\n* Patients with drug-induced hyperuriceamia (those taking anti-TB agents, low dose aspirin, cytotoxic chemotherapy, diuretics, immunosuppressants, fructose, lactate infusion, testosterone or xylitol).\n* Non-obese patients with BMI \\>30 kg\u002Fm2.\n* Pregnant or lactating women.","ALL","18 Years","65 Years",{"count":73,"type":74},60,"ESTIMATED","INTERVENTIONAL",[77],"PHASE2","Gout is a systemic disease that results from the deposition of monosodium urate crystals (MSU) in tissues. Increased serum uric acid (SUA) above a specific threshold (\\>6.8 mg\u002Fdl) is a requirement for the formation of uric acid crystals. MSU crystals can be deposited in all tissues mainly in and around the joints forming tophi. Early presentation of gout is an acute joint inflammation that is quickly relieved by non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine. Lowering SUA levels below deposition threshold either by dietary modification or using serum uric acid lowering drugs is the main goal in management of gout. This results in dissolution of MSU crystals preventing further attacks",[80],"Gout","2025-06-21",{"date":83,"type":84},"2025-06-24","ACTUAL",{"date":86,"type":84},"2025-05-30",{"date":88,"type":74},"2026-12-20",{"name":32,"class":6},1]